Mendel vs Triomics (2026)
Both read the unstructured chart and trace each answer back to the record, for chart review and trial prescreening. Mendel's Hypercube platform is general purpose: it pairs large language models with symbolic reasoning over a clinical hypergraph, highlights the evidence behind every answer, and can run in the customer's own environment. Triomics is built for oncology. OncoLLM, tuned on each institution's records, reads every note, report, scan and fax, and Prism screens every scheduled patient against every open trial daily and delivers a cited worklist inside Epic, OncoEMR or iKnowMed, with pre charting and registry abstraction from the same reading. Both have outside evidence. A randomized evaluation led by the University of Pennsylvania, published in Nature Communications in 2026, tested Mendel in prescreening, and Triomics's matching method is published in npj Digital Medicine. Chart abstraction across many conditions points to Mendel. Oncology trial screening inside the EHR points to Triomics.
- Hypercube is a general platform for chart review, cohort building and trial prescreening across conditions, and it can run in the customer's own environment so data never leaves.
- Symbolic reasoning over a clinical hypergraph sits beside the language model, and every answer is traced to highlighted evidence in the original record.
- A randomized evaluation led by the University of Pennsylvania, published in Nature Communications in 2026, compared AI alone, human alone and combined prescreening.
- Prism screens every scheduled patient against every open trial daily and delivers a cited worklist inside Epic, OncoEMR or iKnowMed.
- OncoLLM is tuned further on each institution's own records, and customers include Memorial Sloan Kettering, Mount Sinai Tisch Cancer Center and more than ten NCI designated centers.
- The same reading powers pre charting through Symphony and NAACCR registry abstraction through Harmony, with registrars verifying the output.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Mendel and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Mendel | Triomics |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2016 | 2021 |
| Headquarters | San Jose, California, United States | New York, New York, United States |
| Website | mendel.ai | triomics.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Mendel, based in San Jose and backed by Oak HC/FT and DCM, sells Hypercube, a platform that reads unstructured patient records for chart review, cohort building and clinical trial prescreening. It pairs large language models with symbolic reasoning over the company's own clinical hypergraph, and ties every answer to highlighted evidence in the original record.
Source: AI Health Index, September 2026
Oncology AI that reads the whole patient chart. OncoLLM, a family of oncology-tuned models tuned further on each institution's records, reads every note, report, scan and fax and returns structured answers with a citation to the line in the chart behind each one.
Source: AI Health Index, September 2026
Questions buyers ask
How are Mendel and Triomics priced and sold?
Mendel's AWS Marketplace listing sells Hypercube as software as a service on contract, with one listed dimension of $1,000,000 a month per Hypercube instance, and says pricing depends on the contract terms agreed with Mendel. The company argues that domain specific models can outperform generic large language models at a scalable cost, but no licensing structure or per record economics are disclosed.
Triomics sells to cancer centers through a demo, as three products on one platform (Prism for trial matching, Symphony for visit preparation, Harmony for registry and quality work), and separately to life sciences companies for enrollment, feasibility, site identification and trial design. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Mendel and Triomics handle patient data?
In Mendel's case, the platform is cloud agnostic and can be hosted inside the customer's own environment so patient data never leaves, and a dedicated capability de identifies PHI from clinical records. Evidence linking, where each answer traces to highlighted source text, functions as a safety control as well as a transparency one, since an unsupported assertion is visibly unsupported.
For Triomics, the company says its models are tuned on each institution's own records with human feedback and deployed as a customized model per partner, and Symphony learns each physician's note style; the privacy page points to a General Privacy Policy on HIPAA. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Mendel and Triomics?
With Mendel, the charts came from one health system and the trial was not powered for efficiency or subgroups. A second Penn study against the EA8191 prostate cancer trial (NCT06561230) is still running.
In Triomics' case, the PRISM trial-matching system was published in npj Digital Medicine (October 2024), reporting 95 percent accuracy in matching patients to trials against expert review. An ASCO 2025 abstract co-authored with a leading academic medical center reports enterprise screening with OncoLLM producing 40 percent more trial matches and a 30 percent lift in trial accruals. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do Mendel and Triomics leave to the clinician?
For Mendel, the study found automation bias: staff followed wrong AI answers on performance status and scored worse than without the AI. What the product may do without a person in routine use, how uncertain answers are routed to a reviewer, and how the automation bias the study found is guarded against are not described in anything readable from outside the company.
With Triomics, each value carries a citation that opens the source line in the chart, and audit trails are native. The company describes this as 'cited, auditable, never a black box', a claim about the basis of each output that the citations back up. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Triomics reports 95 percent accuracy for trial matching in npj Digital Medicine and 94 percent across more than 100 data elements in a preprint, figures that describe studied configurations rather than every institution tuned deployment.
Mendel publishes no SOC 2, ISO 27001 or HITRUST attestation and no business associate terms for the case where it hosts the data, while Triomics requires a signed business associate agreement before real data is used and names no certification on its public pages. Neither publishes a rate card on its own site, and Mendel's AWS Marketplace listing shows one contract dimension of $1,000,000 a month per Hypercube instance.